Gastrointestinal Cancer Update

Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)Management of HER2-Positive Gastroesophageal Cancer (25:11)Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.CME information and select publications

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:Introduction (0:00)Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)Utility of Tumor Treating Fields in PAD Management (1:13:58)CME information and select publications

Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics:Introduction (0:00)Biomarker Evaluation in Localized and Metastatic Disease (1:49)Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37)Other Available Therapeutic Approaches — Dr Shitara (33:22)CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:Introduction (0:00)HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54)Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39)CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics:Introduction (0:00)Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45)Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08)Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42)CME information and select publications